Traws Pharma, Inc. 8-K

What Happened Traws Pharma, Inc. (TRAW) announced on June 12, 2026, that it has deferred the planned test of its antiviral candidate tivoxavir marboxil in a Phase 2a human influenza challenge study. The decision followed a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA). The company issued a press release on June 12, 2026, which was attached as Exhibit 99.1 to its Form 8-K filing.

Key Details

• Filing: Current Report on Form 8-K filed June 12, 2026 (Exhibit 99.1 = press release).
• Program: Planned Phase 2a human influenza challenge study of tivoxavir marboxil has been deferred.
• Reason: Deferred due to a negative review by the UK MHRA.
• Disclosure type: Regulation FD disclosure under Item 7.01 of Form 8-K.

Why It Matters A deferred Phase 2a study means the company’s clinical development timeline for tivoxavir marboxil is paused pending regulatory resolution, which could delay data readouts and any related milestones. For investors, this is a material update about the status of Traws Pharma’s lead program and may affect near-term expectations for clinical progress; the company provided the information via its June 12, 2026 press release and Form 8-K.